Epidemiological Study of Malignant Gliomas in Korea Using Nationwide Dataset from 2007 to 2017

Abstract

Background The purpose of the study was to investigate the incidence, prevalence, and survival of malignant gliomas (MGs) using population-based Korean National Health Insurance Database (NHID) data. Methods Using the Korean NHID, we identified patients with MG as C71 codes in KCD 5–7 according to ICD-10 from January 1, 2007 to December 31, 2017. Epidemiological characteristics of MG, including annual incidence, prevalence, mortality rates, and survival rates, were collected and analyzed according to socioeconomic state (SES) and treatments received. Results We identified 45,066 newly diagnosed-MG patients from 2007 to 2017, for an age-adjusted incidence of 7.47 per 100,000 people. The mean age at diagnosis was 54 years. The male to female ratio was 1.11. Mortality and survival probability were analyzed among total subjects and in subgroups. The mortality rates were lower in female than that of male patients (hazard ratio, 0.69; 95% confidence interval, 0.67–0.71), and in younger age population and in higher income group. Patients operated had a slightly higher survival rate. The 1-, 3-, 5-, and 10-year survival rates were estimated at 63.4%, 46.2%, 39.4%, and 34.8%, respectively. This is the first population-based study to determine the incidence and prevalence of MG according to epidemiological characteristics in Korea using NHID. Conclusion Our study found that female sex and high SES were factors that significantly lowered the mortality rate in MG, and younger groups and operated patients showed significantly higher survival rates.

Population Prevalence, Cancer Risk, and Mortality Risk of Turner Syndrome in South Korean Women Based on National Health Insurance Service Data

“… 26 Other factors, such as smoking, obesity, and family history of cancer (genetic tendency), may also be considered as important factors. However, based on similar studies, 21 27 28 we considered income, residence, and DM would be sufficient for interpreting the data. Cancer incidence and mortality are presented as the number of cases per 1000 persons, adjusted in consideration of the observation period (person-years).…”

Karakteristik Pasien Glioma di RSUD Ulin Banjarmasin Tahun 2018-2020

“…Sebuah penelitian menyebutkan manifestasi klinis yang paling sering ditemukan pada penderita glioma adalah kejang dan kelainan kognitif. 14 Sakit kepala pada penderita glioma merupakan gejala yang tidak umum. 14 Pasien yang mengalami kejang memiliki umur yang lebih muda daripada pasien yang mengalami gangguan kognitif dan ditemukan korelasi yang bermakna antara grading dari tumor dan manifestasi klinis dari penderita glioma.…”

“…14 Sakit kepala pada penderita glioma merupakan gejala yang tidak umum. 14 Pasien yang mengalami kejang memiliki umur yang lebih muda daripada pasien yang mengalami gangguan kognitif dan ditemukan korelasi yang bermakna antara grading dari tumor dan manifestasi klinis dari penderita glioma. 13 Dari hal ini kita dapat mengetahui kemungkinan tingkat keparahan glioma melalui manifestasi klinis yang dialami oleh pasien.…”

“…12 Di Korea menyebutkan bahwa diantara tahun 2007 dan 2017 dari 45.066 pasien dengan Malignant glioma, 25.294 pasien dinyatakan meninggal dan kasus ini memiliki Mortality Rate sebesar 188,15 per 1000 pasien. 14 Mengutip dari Pedoman Nasional Pelayanan Kedokteran (PNPK) Tumor Otak 2019, "Meskipun tumor otak primer dan metastasis secara signifikan menyebabkan morbiditas dan mortalitas, namun informasi epidemiologi tumor otak masih kurang, oleh karena pendataan kasus tumor otak masih belum wajib di beberapa negara termasuk di Indonesia. Selain itu, pencatatan tumor otak sering terbatas hanya tumor otak ganas saja, sehingga tumor otak jinak sering diabaikan".…”

The Current State of Adult Glial Tumor Patients’ Care in Kazakhstan: Challenges in Diagnosis and Patterns in Survival Outcomes

“…The median overall survival time of low-grade glioma, anaplastic glioma, and glioblastoma were 78.1, 37.6, and 14.4 months in China [ 8 ], while in England and Wales, the median survival for astrocytoma, oligodendroglioma, and oligoastrocytoma was 4.6 months, 42 months, and 35.8 months, respectively [ 9 ]. The 1-, 3-, 5-, and 10-year survival rates for malignant gliomas were estimated at 63.4%, 46.2%, 39.4%, and 34.8% in South Korea [ 10 ], while the 2-year survival for Swedish people that were diagnosed with high-grade glioma was 19,5% [ 11 ]. According to the previous study, the 1-year survival for patients with malignant CNS tumors in Kazakhstan was 56.5% overall, 79.5% for lower grades, and 33.1% for grades 3 and 4 [ 12 ].…”